Clinical Trials Pipeline & In-Development

HM15275

also known as: HM-15275

Hanmi's triple-agonist GLP-1/GIP/glucagon candidate, mechanistically analogous to retatrutide — Phase 2 in obesity with a monthly-dosing ambition enabled by Hanmi's LAPSCOVERY platform.

A triple GLP-1 / GIP / glucagon receptor agonist peptide in Phase 2 by Hanmi Pharmaceutical — mechanistically the same class as retatrutide (Lilly) — distinguished by Hanmi's LAPSCOVERY Fc-conjugation platform, which is designed to support less-than-weekly dosing intervals (potentially monthly).

Mechanism of action

Balanced triple agonism at GLP-1, GIP, and glucagon receptors — same pharmacological concept as retatrutide. Glucagon agonism adds an energy-expenditure component that drives greater weight loss than dual GLP-1/GIP approaches in preclinical work.

Primary uses

Obesity (Phase 2)

Typical dosing

weekly or less frequent (subcutaneous)

Phase 2 doses not publicly finalized.

Regulatory status

Not approved. Phase 2 in obesity.

References

[manufacturer] Hanmi Pharmaceutical pipeline page — HM15275 triple agonist.

Related peptides

Retatrutide

An investigational triple hormone agonist that produced ~24% weight loss at 48 weeks in Phase 2 — the largest in any single-agent obesity trial to date.

Survodutide

A once-weekly GLP-1/glucagon co-agonist in late-stage trials for obesity, type 2 diabetes, and MASH.

Mazdutide

A weekly GLP-1/glucagon dual agonist approved in China for obesity (2025); the first OXM-mimetic to reach market.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.